{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:38:45Z","timestamp":1775381925331,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":1193,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.7861\/clinmed.2020-0309","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T13:50:11Z","timestamp":1604411411000},"page":"e84-e87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Rationale for the use of sphingosine analogues in COVID-19 patients"],"prefix":"10.1016","volume":"21","author":[{"given":"Deborah R","family":"Tasat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan S","family":"Yakisich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmed.2020-0309_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbi.2020.04.046","article-title":"Current status of potential therapeutic candidates for the COVID-19 crisis","volume":"87","author":"Zhang","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.7861\/clinmed.2020-0309_bib2","first-page":"327","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.7861\/clinmed.2020-0309_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the \u2018cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"10.7861\/clinmed.2020-0309_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev-pathol-011110-130158","article-title":"The acute respiratory distress syndrome: pathogenesis and treatment","volume":"6","author":"Matthay","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.7861\/clinmed.2020-0309_bib5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40071","article-title":"Review: cytokine storm syndrome: looking toward the precision medicine era","volume":"69","author":"Behrens","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.7861\/clinmed.2020-0309_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","volume":"146","author":"Li","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.7861\/clinmed.2020-0309_bib7","article-title":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients","author":"Chen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.7861\/clinmed.2020-0309_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/MAT.0000000000001185","article-title":"Extracorporeal membrane oxygenation in the treatment of severe pulmonary and cardiac compromise in COVID-19: Experience with 32 patients","volume":"66","author":"Jacobs","year":"2020","journal-title":"ASAIO J"},{"key":"10.7861\/clinmed.2020-0309_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"10.7861\/clinmed.2020-0309_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","article-title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab","volume":"101","author":"Cellina","year":"2020","journal-title":"Diagn Interv Imaging"},{"key":"10.7861\/clinmed.2020-0309_bib11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ajh.25833","article-title":"Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab","volume":"95","author":"De Luna","year":"2020","journal-title":"Am J Hematol"},{"key":"10.7861\/clinmed.2020-0309_bib12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/ajt.15935","article-title":"Covid-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine","volume":"20","author":"Fontana","year":"2020","journal-title":"Am J Transplant"},{"key":"10.7861\/clinmed.2020-0309_bib13","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"key":"10.7861\/clinmed.2020-0309_bib14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/annrheumdis-2020-217442","article-title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD","volume":"79","author":"Mihai","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmed.2020-0309_bib15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"10.7861\/clinmed.2020-0309_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25907","article-title":"Letter to the editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab","author":"Morrison","year":"2020","journal-title":"J Med Virol"},{"key":"10.7861\/clinmed.2020-0309_bib17","first-page":"CD009371","article-title":"Fingolimod for relapsing-remitting multiple sclerosis","volume":"4","author":"La Mantia","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.7861\/clinmed.2020-0309_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.autrev.2017.02.007","article-title":"Multiple sclerosis in the real world: A systematic review of fingolimod as a case study","volume":"16","author":"Ziemssen","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.7861\/clinmed.2020-0309_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","article-title":"The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives","volume":"185","author":"Huwiler","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.7861\/clinmed.2020-0309_bib20","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.4049\/jimmunol.1102754","article-title":"Sphingosine analogue AAL-R increases TLR7-mediated dendritic cell responses via p38 and type I IFN signaling pathways","volume":"188","author":"Seo","year":"2012","journal-title":"J Immunol"},{"key":"10.7861\/clinmed.2020-0309_bib21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1073\/pnas.0812689106","article-title":"A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection","volume":"106","author":"Marsolais","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.7861\/clinmed.2020-0309_bib22","doi-asserted-by":"crossref","first-page":"3701385","DOI":"10.1155\/2017\/3701385","article-title":"FTY720 attenuates angiotensin II-induced podocyte damage via inhibiting inflammatory cytokines","volume":"2017","author":"Su","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.7861\/clinmed.2020-0309_bib23","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1111\/jcmm.13596","article-title":"S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2\/4-NF\u03baB signalling","volume":"22","author":"Dong","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.7861\/clinmed.2020-0309_bib24","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/CCM.0000000000000097","article-title":"FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury","volume":"42","author":"Wang","year":"2014","journal-title":"Crit Care Med"},{"key":"10.7861\/clinmed.2020-0309_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.intimp.2018.06.036","article-title":"Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models","volume":"63","author":"Huang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.7861\/clinmed.2020-0309_bib26","doi-asserted-by":"crossref","first-page":"102073","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.7861\/clinmed.2020-0309_bib27","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1212\/NXI.0000000000000753","article-title":"COVID-19 infection in a patient with multiple sclerosis treated with fingolimod","volume":"7","author":"Barzegar","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.7861\/clinmed.2020-0309_bib28","doi-asserted-by":"crossref","first-page":"102414","DOI":"10.1016\/j.msard.2020.102414","article-title":"Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod","volume":"45","author":"Mallucci","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.7861\/clinmed.2020-0309_bib29","doi-asserted-by":"crossref","first-page":"117011","DOI":"10.1016\/j.jns.2020.117011","article-title":"Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide","volume":"416","author":"Bollo","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.7861\/clinmed.2020-0309_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s42399-020-00369-y","article-title":"Treatment-refractory headache in the setting of COVID-19 pneumonia: migraine or meningoencephalitis","author":"Arca","year":"2020","journal-title":"SN Compr Clin Med"},{"key":"10.7861\/clinmed.2020-0309_bib31","doi-asserted-by":"crossref","first-page":"577282","DOI":"10.1016\/j.jneuroim.2020.577282","article-title":"Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection","volume":"345","author":"Chiarini","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.7861\/clinmed.2020-0309_bib32","doi-asserted-by":"crossref","first-page":"102182","DOI":"10.1016\/j.msard.2020.102182","article-title":"A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19","volume":"42","author":"Valencia-Sanchez","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.7861\/clinmed.2020-0309_bib33","article-title":"Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal","author":"Gomez-Mayordomo","year":"2020","journal-title":"J Med Virol"},{"key":"10.7861\/clinmed.2020-0309_bib34","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.msard.2020.102180","article-title":"Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod","volume":"42","author":"Foerch","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.7861\/clinmed.2020-0309_bib35","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role","volume":"42","author":"Novi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.7861\/clinmed.2020-0309_bib36","article-title":"Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture","author":"Risner","year":"2020","journal-title":"bioRxiv"},{"key":"10.7861\/clinmed.2020-0309_bib37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fimmu.2020.01102","article-title":"Battling COVID-19 pandemic: sphingosine-1-Phosphate analogs as an adjunctive therapy","volume":"11","author":"Naz","year":"2020","journal-title":"Front Immunol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824033967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824033967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmed.2020-0309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:57:59Z","timestamp":1745391479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824033967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1470211824033967"],"URL":"https:\/\/doi.org\/10.7861\/clinmed.2020-0309","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for the use of sphingosine analogues in COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmed.2020-0309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2021. All rights reserved.","name":"copyright","label":"Copyright"}]}}